Table 1.
Average zones of inhibition (AZOIs) of novel pyrazole, pyrazolo[1,5-a]pyrimidine derivatives, and control antibiotics against clinical pathogenic bacteria recorded in mm.
| Compound No. | Diameter of Inhibition Zones in mm | |||||
|---|---|---|---|---|---|---|
| Gram-Positive Bacteria | Gram-Negative Bacteria | |||||
| E. faecalis DH-5478 | S. aureus DH-432 | S. pyogenes DH-3467 | A. baumannii DH-243 | E. coli DH-5987 | P. aeruginosa DH-5698 | |
| 3a | 30.6 | 31.1 | 31.5 | 29.3 | 32 | 30.8 |
| 3b | 24.4 | 25.2 | 24.7 | 23.1 | 26.9 | 25.1 |
| 3c | 21.3 | 23.8 | 22.6 | 22.5 | 24.7 | 23.2 |
| 4 | 22.1 | 24.7 | 23.4 | 21.3 | 22.4 | 20.5 |
| 5a | 28.2 | 28.6 | 28.9 | 28.0 | 29.9 | 28.3 |
| 5b | 25.4 | 26.2 | 24.1 | 23.4 | 25.7 | 24.7 |
| 6 | 29.5 | 29.5 | 30.2 | 28.8 | 31.0 | 28.8 |
| 7 | 23.0 | 25.3 | 22.8 | 24.5 | 25.8 | 24.0 |
| 8a | 20.6 | 22.0 | 21.4 | 19.7 | 23.4 | 21.6 |
| 8b | 17.3 | 19.5 | 18.7 | 16.5 | 20.1 | 18.4 |
| 8c | 15.1 | 16.1 | 15.4 | 15.2 | 17.8 | 16.3 |
| 9a | 28.7 | 29.1 | 29.3 | 28.4 | 30.4 | 28.5 |
| 9b | 24.3 | 25.0 | 25.7 | 23.0 | 26.5 | 25.4 |
| 9c | 23.1 | 24.2 | 23.5 | 23.9 | 25.2 | 24.1 |
| 10a | 29.8 | 30.6 | 30.7 | 29.1 | 31.5 | 30.1 |
| 10b | 25.1 | 26.8 | 26.3 | 24.2 | 27.1 | 26.3 |
| E | 11 | 12 | 10.5 | NA | NA | NA |
| AK | NA | NA | NA | 13 | 11 | 14 |
| DMSO | -ve | -ve | -ve | -ve | -ve | -ve |
E: Erythromycin (S ≥ 23 mm, I = 14–22 mm, R ≤ 13, for S. aureus and E. faecalis) and (S ≥ 21 mm, I = 16–20, R ≤ 15, for S. pyogenes); AK: Amikacin (S ≥ 17 mm, I = 15–16 mm, R ≤ 14 mm); DMSO: dimethyl sulfoxide; NA: not applicable; -ve: no zones of inhibition.